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Cytotoxicity of nubein6.8 peptide isolated from the snake venom of Naja 
nubiae on melanoma and ovarian carcinoma cell lines 
 
Abstract 
This study was conducted to examine the cytotoxic effects of Nubein6.8 isolated from the venom 
of the Egyptian Spitting Cobra Naja nubiae on melanoma (A375) and ovarian carcinoma cell lines 
and to reveal its mode of action. The size of Nubein6.8 (6801.8 Da) and its N-terminal sequence 
are similar to cytotoxins purified from the venom of other spitting cobras. Nubein6.8 showed a 
high significant cytotoxic effect on A375 cell line and moderate effect on A2780. A clonogenic 
assay showed that Nubein6.8 has a significant long-term potency on A375 cell survival when 
compared to A2780. The molecular intracellular signaling pathways of Nubein6.8 have been 
investigated using Western blotting analysis, flow cytometry, and microscale protein labeling. This 
data revealed that Nubein6.8 has DNA damaging effects and the ability to activate apoptosis in 
both tumor cell lines. Cellular uptake recordings revealed that the labeled-Nubein6.8 was 
intracellularly present in A375 cells while A2780 displayed resistance against it. SEM examination 
showed that Nubein6.8 was found to have high accessibility to malignant melanoma cells. The 
apoptotic effect of Nubein6.8 was confirmed by TEM examination that revealed many evident 
characteristics for Nubein6.8 apoptotic efficacy on A375 cell sections. Also, TEM reflected many 
resistant characteristics that faced Nubein6.8 acquisition through ovarian carcinoma cell sections. 
Accordingly, the snake venom peptide of Nubein6.8 is a promising template for developing 
potential cytotoxic agents targeting human melanoma and ovarian carcinoma.  
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1. Introduction 
Cancer is considered to be one of the most common causes of death worldwide. Based on the 
global cancer statistics of GLOBOCAN, the number of deaths attributed to cancer was around  8.2 
million in 2012 (Torre et al., 2015) and has risen to 9.6 million cancer deaths in 2018 (Bray et al., 
2018). Various therapeutic strategies including chemotherapy, radiotherapy, and immunotherapy 
that are being used to treat cancer   have numerous side effects. In addition, tumors often acquire 
resistance against chemotherapeutics (Lai et al., 2012). Thus, the discovery and development of 
specific/safe anticancer agents is one of the main objectives of pharmaceutical and 
biotechnological industry. The ability of different natural toxins derived from various venomous 
animals (such as frogs, scorpions and snakes) to alter the main hallmarks of cancer cells makes 
them as good templates for developing potential anticancer agents.  
 
According to venomics studies, snake venom is a cocktail of different bioactive molecules which 
mainly include peptides/proteins (such as disintegrins, cysteine-rich secretory proteins, natriuretic 
peptides, lectins and three-finger toxins (3-FTxs) and enzymes (such as phospholipase A2, L-
amino acid oxidases, serine proteases, hyaluronidases and acetylcholinesterases) (Calvete et al., 
2007; Sanhajariya et al., 2018). There are several peptides have been characterized from the venom 
of elapidae and viperidae snakes targeting various types of cancer cells through certain molecular 
pathways (such as inducing cell membrane and DNA damage, upregulation proapoptotic signals, 
inhibition proliferation and metastasis, blocking DNA synthesis and promoting cell cycle arrest) 
(Calderon et al., 2014; Liu et al., 2014; Ma et al., 2017). The differential cytotoxicity of these 
molecules toward tumor cells rather than normal cells makes them potential candidates to be 
explored for their therapeutic potential (Calderon et al., 2014).  
 
Of these peptides, snake venom disintegrins (as anti-angiogenesis and metastasis agents, see 
review of Ma et al., 2017) which include salmosin (8.0 kDa, Agkistrodon halys brevicaudus), 
albolabrin (7.5 kDa, Trimeresurus albolabris), lebein (7.0 kDa, Macrovipera lebetina), saxatilin 
(7.7 kDa, Gloydius halys) and triflavin (7.57 kDa, Protobothrops flavoviridis). Cathelicidin-BF 
(30 amino acids) was purified from the snake venom of Bungarus fasciatus and showed in vitro 
and in vivo activity (as an anti-proliferative, anti-angiogenic and anti-migratory agent) on B16F10 
melanoma cell line (Wang et al., 2013). Also, cardiotoxin III (CTX III belongs to 3-FTxs) which 
purified from the snake venom of Naja naja atra induced apoptosis in different cancer cell lines 
(Colo205 human colorectal cancer, HL-60 human leukemia and MCF-7breast cancer) through 
mitochondrial and endoplasmic reticulum mediated pathways (Tsai et al., 2006;  Chien et al., 
2008;; Chiu et al., 2009).  
 
Currently  there are no FDA approved anticancer drugs  derived from snake venoms, however, 
three promising candidates (disintegrins), ATN-161, GLPG0187 and vicrostatin which were 
derived from snake venom are currently being investigated, using in vivo studies and clinical trials, 
(Phase I, II and preclinical studies) as potent anticancer drugs. Disintegrins have been shown to 
effect angiogenesis, invasion, and metastasis of various cancer types including malignant glioma, 
breast and ovarian carcinoma (see review of Ma et al., 2017).  Hence, there is a clear rational for 
investigating snake venoms as potential new effective therapeutics for cancer. Therefore, the main 
objectives of this research are: (i) to evaluate the venom derived peptide (Nubein6.8) from the 
Egyptian Spitting Cobra Naja nubiae on different types of cancer cells (human malignant 
melanoma and ovarian cancer cell lines), and (ii) to determine a mechanism of action of Nubein6.8 
using various molecular and imaging approaches.  
 
2. Materials and Methods 
2.1. Collection of snakes and venom preparation 
 
About 20 snakes of the Egyptian Spitting Cobra Naja nubiae were collected from Aswan 
Governate, Egypt. The snakes were carefully kept in large wooden boxes at Zoology Department 
(Suez Canal University, Egypt). The snakes were fed on mice and provided with water every 15 
days.  The venom was mechanically collected in a 50 mL glass sterilized beaker. The collected 
venom was freeze-dried and then stored at -20°C until used. 
 
2.2. Separation and proteomic analysis of Nubein6.8  
 
N. nubiae crude venom (50 mg dissolved in 500 µL dH 2O) was fractionated using a Sephadex G-
50 column (1.5 x 100 cm; Shimadzu Liquid Chromatograph). The column was equilibrated with 
0.1 M ammonium acetate buffer (30 mL/hr) and fractions were collected (5 mL), the column 
effluent was monitored at 280 nm. The collected venom fractions were lyophilized and stored at -
20°C until used. Five fractions were obtained (F1-F5) and F3 (Nubein6.8) was further purified. 
One mg/mL dH2O of fraction F3 was applied to a Water Xbridge BEH300-C18 column (4.6 x 50 
mm, 3.5 μm particle size). The fractions were eluted using a linear gradient of buffer A (0.05% 
TFA in dH2O) and 60% buffer B (0.05% TFA in acetonitrile) for an hour with a flow rate 1 mL/min. 
The identification of Nubein6.8 was done by MALDI–TOF/MS (Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight mass spectrometer), LTQ Orbitrap Mass Spectrometer and 
N-terminal sequencing (first 6 amino acids) by Alta Bioscience Ltd, University of Birmingham, 
UK.  
 
2.3. Cell Culture 
The experimental cell lines: the human tumor cell lines (A375 malignant melanoma, A780 ovarian 
carcinoma and PANC1 pancreatic carcinoma) and PNT2 normal cell line (model of human 
differentiated normal epithelia) used in the present study were obtained from the European 
Collection of Cell Cultures (ECACC), UK. The culture medium used for all cell lines’ growing 
and culturing was BioWhittaker® RPMI 1640 medium supplemented with 10% (v/v) foetal bovine 
serum, 1% (v/v) kanamycin sulfate, 1% (v/v) non-essential amino acid, 1% (v/v) L-glutamine, and 
1% (v/v) sodium pyruvate. The cell lines were cultured in cell culture flasks (25 cm2  and 75 cm2), 
12-well and 96-well plates and then incubated in a CO2 incubator (37°C, 5% CO2).  
 
2.4. Cell viability and haemolysis assays 
To assess changes in metabolic activity of A375, A780, PANC1 and PNT2 cell lines, MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5Diphenyltetrazolium Bromide) viability assay was carried out (n= 
3) by seeding cells (75 µL/well) in 96-well plates (1 x104, 1 x104, 2 x104, 6 x103 cells/well, 
respectively) for 24 hrs incubation (37°C, 5% CO2) and adding 25 µL/well of 12 serial 
concentrations (0.007-14.7 µM) of Nubein6.8 to the incubated cells (100 µL/well). After heating 
the MTT solution to 37°C until a clear solution was obtained, the assay was performed, protected 
from light, after 24 hrs incubation (37°C, 5% CO2), by adding (10 µL/well) of the MTT solution. 
After 24 hrs incubation (37°C, 5% CO2), 200 µL of DMSO (Dimethyl sulfoxide) was  added into 
the culture medium (final volume 300 µL/well).  Appropriate control wells were prepared at the 
same time. The colorimetric signals were measured, by using Absorbance-based 
SpectraMax®M5 Microplate Reader, at 570 nm then at 630 nm for background absorbance. To 
obtain normalized absorbance values, the background absorbance was subtracted from the signal 
absorbance, then divided by MTT activity negative control and multiplied by 100 to calculate % 
cytotoxicity. Cytotoxicity percentage was identified by measuring the average values of half of 
the effective concentration (EC50) from plotting % cytotoxicity values obtained from dose-
response curves. Using the Tecan plate reader (Infinite M200, Switzerland, at 570 nm), 
haemolytic activity of Nubein6.8 (0.007-14.7 µM; n=3) was examined on sheep red blood cells 
(Corzo et al., 2001). Triton X-100 (10%) and bidistilled water were used as positive and negative 
controls, respectively. Hemolysis percentage was calculated using the following formula: 
Hemolysis % = [(absorbance of treated sample – absorbance of negative control/ (absorbance of 
positive control– absorbance of negative control)] x 100. 
 
2.5. Clonogenic assay 
Clonogenic assay (Franken et al., 2006) was conducted to determine the long-term potency of the 
cytotoxic agents on cell survival, growth rate, cell proliferation and therefore metastasis of tumor 
cell lines under investigation. Cells were cultured (n= 3) into triplicate 25 cm2 flasks and incubated 
(37°C, 5% CO2) until reaching 60-70% confluence. Then, the culture media were replaced with 
fresh media containing six different concentrations (from 0.01 to 1.8 µM) of Nubein6.8. After 24 
hrs incubation (37°C, 5% CO2), the culture media were aspirated, the cells were washed with 0.5% 
HBSS (0.5% MgCl2 and CaCl2-free Hank’s Balanced Salt Solution) and detached by incubation 
(37°C, 5% CO2) with 0.25% TrypLE
TM Express from 1-5 mins according to type of cell lines, and 
then 2X fresh media were added to counteract the Trypsin action. After counting cells using the 
hemacytometer, calculated volume containing an appropriate number of viable cells were seeded 
in triplicate 60 mm Petri dishes (400 cells/dish) for each treatment concentration, and then 
incubated at 37°C and 5% CO2. Following 10-14 days of incubation (37°C, 5% CO2), colony 
formation was assessed; at least 50 colonies developed in negative control dishes (untreated 
colonies). Then, the culture media were aspirated; the colonies were washed with HBSS, fixed 
with methanol for 10 mins, and stained with Giemsa for 10 mins. The stain was carefully aspirated, 
and the dishes were rinsed with water, then formed colonies were counted manually after dishes 
drying. Plating efficiency (PE) and survival fraction (SF) were calculated through the following 
equations: PE= Average no. of control colonies formed / No. of seeded cells. SF= Average no. of 
colonies formed after treatment / (No. of seeded cells x PE).  
 
 
2.6. Western blotting analysis 
The western blotting analysis was done to evaluate the stimulatory effect of Nubein6.8 on the 
phosphorylation of the histone variant (H2AX) that produces gamma Histone (γH2AX) or 
phospho-Histone H2AX (as a specific marker for DNA damage). Cells were seeded (500 µL/well, 
n= 3) in 12-well plates for 24 hrs incubation (37°C, 5% CO2), and treated with the 6 different 
selected concentrations (from 0.01 to 1.8 µM) of Nubein6.8. Additional cells’ triplicate wells for 
negative control cells (untreated) and other triplicate wells for the positive control (treated with 
Staurosporine as positive DNA damaging control) were plated. After 24 hrs incubation (37°C, 5% 
CO2), the plates placed on ice to stop the reaction, then the culture media were aspirated, the cells 
were washed with 250 µL cold HBSS, and 150 µL of Laemmli’s sample buffer (63 mM Tris-HCl, 
(pH 6.8), 2 mM Na-4P2O7, 5 mM EDTA (ethylenediaminetetraacetic acid), 10% (v/v) glycerol, 
2% (w/v) SDS (sodium dodecyl sulfate), 50 mM DTT (dithiothreitol) and 0.007% (w/v) 
bromophenol blue) was added to each well to get whole cell extracts. Aliquots of cell extract 
sample volume (20-25 μL) were electrophoresed through SDS-PAGE at a constant voltage of 130 
V. Following the electrophoretic transfer of proteins to the nitrocellulose membrane, the protein 
transfer membrane incubated with specific primary antibody (anti-phospho-histone 
H2AX/Ser139) overnight in cold room conditions. The blot was then incubated for another 2 hrs 
with secondary peroxidase-conjugated IgG anti-mouse, directed against the first immunoglobulin. 
Immunoreactive proteins were detected by incubation in enhanced chemiluminescence (ECL) 
reagents for 3 mins with gentle agitation. The membrane was then mounted onto an exposure 
cassette and covered with cling film, then exposed to X-ray film for the required time under dark 
room conditions and developed using X-OMAT processor (KODAK M35-M X-OMAT). Then, 
the relative separated bands intensity was measured by ScnImage software. The nitrocellulose 
membrane was then stripped for detection of loading control protein, by incubated in 15 mL of 
stripping buffer (0.05M Tris-HCl, 2% SDS, and 0.1M of β-mercaptoethanol), at 60 oC for 1 hr 
with shaking. GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was used as loading control. 
The blots were undergone the immunological detection protocol as explained previously. 
 
2.7. Cell cycle analysis 
Effect of Nubein6.8 on cell cycle progression was evaluated using FACS (Fluorescence-Activated 
Cell Sorting Analysis)-Flow. Cells were cultured (n= 3) into triplicate 25 cm2 flasks and incubated 
(37°C, 5% CO2) until reaching 60-70% confluence. Then, the culture media were replaced with 
fresh media containing the six different selected concentrations (from 0.01 to 1.8 µM) of 
Nubein6.8. After 24 hrs incubation (37°C, 5% CO2), the culture media were aspirated, the cells 
were washed with 0.5% HBSS and detached by incubation (37°C, 5% CO2) with 0.25% TrypLE
TM 
Express from 1-5 mins according to the cell line, and then 2X fresh media were added to counteract 
the Trypsin action. Cell suspensions were centrifuged at 1500 rpm for 5 mins, and supernatants 
were removed, and the cells were fixed in ice-cold 70% (v/v) ethanol. 2 hrs before flow cytometric 
analysis, the cells were resuspended in FACS tubes with 1 mL of staining solution (propidium 
iodide (PI) solution (50 µg/mL) and RNase A solution (100 µg/mL) in phosphate buffered saline 
(PBS). Then, the tubes containing cell suspension were incubated on ice and in the dark for at least 
1 hr. Flow cytometric analysis was carried out using a FACScan (Becton Dickinson Systems, 
Cowley, UK), and data were analyzed using CellQuest Pro software (version 5.1.1; BD 
Biosciences).  
 
2.8. Cellular uptake assay 
 
Nubein6.8 was labeled with the molecular probe of Alexa Fluor® 488 Microscale Protein Labeling 
kit according to the manufacturer’s instructions. The molecular infiltration and the fluorescence 
distribution of labeled-fractions throughout the cells allowed monitoring of their localization into 
the cell membrane, cytoplasm, and nuclear envelope. In this regard, the actin cytoskeleton was 
stained with Phalloidin, DylightTM 554 Conjugated red fluorescent stain, and the blue-fluorescent 
DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) nucleic acid stain was used to stain the 
nuclei. Cells were seeded (500 µL/well, n= 3) on coverslips in triplicate wells of 12-well plates for 
24 hrs incubation (37°C, 5% CO2), and treated with the six different concentrations (from 0.01 to 
1.8 µM) of labeled-Nubein6.8 (500 µL/well). After 24 hrs incubation (37°C, 5% CO2), the culture 
media were aspirated from cells grown on coverslips, the cells were washed three times with 250 
µL HBSS, 5 mins for each, and fixed by adding of 150 µL of 3.7% formaldehyde to each well for 
10 mins. The cell coverslips were rinsed three times in PBS, 5mins for each, and then the cell 
membranes were permeabilized by immersion in 0.2% triton X-100 in PBS for 5 mins. The triton 
was aspirated, and the cells were rinsed again three times in PBS, 5 mins for each. The cell 
coverslips were then ready to undergo the sub-cellular specific staining; DAPI counterstaining 
alongside phalloidin conjugated protocol. Labeling imaging was carried out using confocal laser 
scanning microscope, with oil immersion objectives.  
2.9. Ultrastructural Microscopy 
2.9.1. Scanning Electron Microscopy (SEM) 
Cells were cultured (n= 3) into triplicate 25 cm2 flasks and incubated (37°C, 5% CO2) until 
reaching 60-70% confluence. Then, the culture media were replaced with fresh media containing 
6 different concentrations (from 0.01 to 1.8 µM) of Nubein6.8 (500 µL/well). Additional cells’ 
triplicate flasks for negative control cells (untreated) were also cultured. After 24 hrs incubation 
(37°C, 5% CO2), the culture media were aspirated, the cells were washed with 0.5% HBSS (0.5% 
MgCl2 and CaCl2-free Hank’s Balanced Salt Solution) and detached by incubation (37°C, 5% CO2) 
with 0.25% TrypLETM Express from 1-5 mins according to the cell line, and then 2X fresh media 
were added to counteract the Trypsin action. Cell suspensions were centrifuged at 5000 rpm for 
10 mins; then the cell pellets were washed twice times in 0.1 M sodium phosphate buffer in dH2O 
(3.1 g NaH2PO4.H2O and 10.9 g Na2HPO4 anhydrous (pH 7.4) with 15 mins intervals, and firstly 
fixed in 3% glutaraldehyde overnight at 4oC. After first fixation time, pellets wash was repeated 
twice in 0.1 M sodium phosphate buffer also with 15 mins intervals, and secondary fixed in 1% 
osmium tetroxide aqueous for 1 hr, all at room temperature. Then, the pellets were dehydrated 
with a series of ascending percentages of ethanol (75%, 95%, and twice times 100%) with 15 mins 
intervals, and then initially placed in 50:50 mixture of 100% ethanol and 100% 
Hexamethyldisilazane for 30 mins, followed by another 30 mins in 100% Hexamethyldisilazane. 
Before mounting, the pellets air dried overnight and were mounted on 12.5 mm stubs and attached 
with Carbon-Sticky Tabs, and then coated in an Edwards S150B sputter coater (with 
approximately 25 nm of gold). SEM imaging examination was carried out using a Philips XL-20 
Scanning Electron Microscope at an accelerating voltage of 20 Kv. 
 
2.9.2. Transmission Electron Microscopy (TEM) 
Cells were cultured (n= 3) and treated with the 6 different concentrations (from 0.01 to 1.8 µM) 
of Nubein6.8 (500 µL/well). The cell pellets were fixed and dehydrated using the same protocol 
of SEM as explained previously, including negative control cell pellets (untreated). After the 15 
mins interval of the dehydration series in 100% ethanol, the pellets were cleared in epoxypropane 
(EPP), then infiltrated in 50:50 mixture of araldite resin and EPP overnight on a rotor, followed 
by repeated infiltration twice times in fresh mixture for 8 hrs, before embedding and curing in a 
60ºC oven for 48-72 hrs. Ultrathin sections were cut, approximately 85 nm thick, on a Leica UC 6 
ultramicrotome onto 200 mesh copper grids. Then, the sections were stained for 30 mins with 
saturated aqueous Uranyl Acetate, followed by Reynold’s Lead Citrate for 5mins. TEM imaging 
examination was carried out using a FEI Tecnai Transmission Electron Microscope (with an 
accelerating voltage of 80 Kv) and acquired using a Gatan Orius digital camera. 
 
2.10. Statistical Analysis 
GraphPad Prism software (version 4) was used in statistical analysis and illustrations. Data were 
expressed as mean ± SE. One-way ANOVA and Dunnett’s Multiple Comparison test were applied 
for multiple comparisons. Differences between groups were considered statistically significant 
with P values less than 0.05. 
 
3. Results 
3.1. Characterization of the snake venom peptide Nubein6.8.  
Nubein6.8  (Fig. 1A and 1B) was characterized by MALDI-TOF/MS (Fig. 1C) and LC-MS 
(Supplementary Fig. 1) to reveal that the protein mass fingerprint of Nubein6.8 was  the dominant 
peptide of nearly 6.8 KDa. N-terminal sequencing of Nubein6.8 resulted in a strong clear 
primary sequence, and the first six amino acids are LKCNQL (Fig. 1D). Sequence alignment of 
the first 6 N-terminal residues of Nubein6.8 showed a strong similarity with cytotoxins purified 
from the venom of other spitting cobras (Fig. 1E). The aligned cytotoxins are UniProt:P01469 
(Cytotoxin 2, Mozambique spitting cobra Naja mossambica; MW 6800 Da), UniProt:P01467 
(Cytotoxin 1, Mozambique spitting cobra Naja mossambica; MW 6826 Da) and UniProt:P01468 
(Cytotoxin 1, Red spitting cobra Naja pallida; MW 6827 Da). 
 
3.2. Cytotoxicity of Nubein6.8 on cancer cell lines (A375 human malignant melanoma, A2780 
ovarian carcinoma, PANC1 pancreatic carcinoma), PNT2 normal cell line (using MTT 
viability assay) and sheep RBCs 
 
Cancer cell lines (A375, A2780 and PANC1), normal cell line (PNT2) and sheep RBCs were 
treated with various concentrations of Nubein6.8 (from 0.007 to 14.7 µM; for 24 hrs) and 
cytotoxicity was evaluated using MTT viability and haemolytic assays (Fig. 2 and 3). The average 
EC50 values of A375 and A2780 were 0.54 ± 0.04 and 1.249 ± 0.06 µM, respectively. Nubein6.8 
showed a slight cytotoxic effect on PANC1 pancreatic carcinoma only in the high concentrations 
(above 3.7 µM; Supplementary Fig. 2 and 3). The cytotoxic effect of Nubein6.8 on PNT2 normal 
cell line was also investigated. The data revealed that cytotoxicity of Nubein6.8 on PNT2 (EC50 
1.45 ± 0.05 µM) was less than its effect on A375 (EC50 0.54 ± 0.04 µM) and A2780 (EC50 1.249 ± 
0.06 µM) cell lines (Fig. 2). Nubein6.8 showed no haemolytic activity on washed sheep RBCs at 
the highest concentration tested (14.7 µM; Supplementary Fig. 4).  
 
3.3. Antimetastatic potency of Nubein6.8 on human malignant melanoma (A375) and ovarian 
carcinoma (A2780) using clonogenic assay 
 
Clonogenic assay showed that there was a significant effect (p<0.01) of Nubein6.8 on A375 tumor 
cell survival  (1.8 µM, survival fraction (SF value) = 0) and continued until the lowest 
concentration tested (0.01 µM, SF value =0.73 ± 0.1). Nubein6.8 also significantly (p<0.01) 
decreased the number of colonized ovarian A2780 tumor cells   at 1.8 and 0.9 µM (SF values = 
0.60 ± 0.04 and 0.70 ±0.06, respectively) when compared with their untreated control cells (Fig. 4 
and Supplementary Fig. 5).  
  
3.4. DNA damage induced by Nubein6.8 on human malignant melanoma (A375) and ovarian 
carcinoma (A2780) using Western Blotting with Anti-phospho-Histone H2AX antibody 
The phosphorylation of histone H2AX is considered as a specific marker for DNA damage 
response and underlies the complex molecular mechanism for DNA repair, after the formation of 
double-strand breaks (DSBs). Therefore, the evaluation of phospho-Histone H2AX  level of the 
tumor cell lines under investigation was to monitor the ability of Nubein6.8 to induce DSBs which 
could lead to genomic instability and consequence cell death.. The data in Fig. 5 illustrate the level 
of phospho-Histone H2AX expression in A375 (Fig. 5A) and A2780 (Fig. 5B) tumor cells treated 
with Nubein6.8. Nubein6.8 induced a significant increase (p<0.01) in phospho-Histone H2AX 
expression at 0.45 - 0.9 µM in melanoma A375 cells and at  0.9 - 1. 8 µM in ovarian carcinoma 
A2780 cells when compared with their negative (untreated cells) and positive (Staurosporine) 
control cells. GAPDH loading control protein assessment revealed that Nubein6.8 positively 
regulated GAPDH translation in both tumor cells and inhibited GAPDH signaling  in A375 cells 
(0.45 - 1. 8 µM) and A2780 cells at highest concentration tested (1.8 µM).  
 
3.5. Genotoxicity of Nubein6.8 on human malignant melanoma (A375) and ovarian 
carcinoma (A2780) using FACS-Flow Cytometry 
Treatment of both A375 and A2780 cell lines with different concentrations (0.01-1.8 µM) of 
Nubein6.8 for 24 hrs induced detectable cell cycle arrest when compared with untreated cells (Fig. 
6). In treated melanoma A375, the number of cells distributed in the S phase remarkably decreased 
(2-fold decrease in melanoma) compared with cells in other phases. Also, in the ovarian carcinoma 
cells, the effective concentrations of nubein6.8 (0.11- 0.9 µM) induced cell cycle blockage at S 
phase and continued to reach G2-M phase. 
 
3.6. Cellular uptake of labeled-Nubein6.8 by human malignant melanoma (A375) and 
ovarian carcinoma (A2780)  
 
The distribution of green fluorescence labeled-Nubein6.8 (0.01-1.8 µM) throughout A375 and 
A2780 tumor cells (Fig. 7) revealed the uptake for this toxin into cellular compartments. The 
effective concentrations (0.11 - 0.9 µM) of labeled-Nubein6.8  was abled to penetrate through cell 
membrane and cytoplasm of both cell types, with  the peptide accumulating in the nucleoli of cell.  
 
3.7. Ultrastructural alteration induced by Nubein6.8 on human malignant melanoma (A375) 
and ovarian carcinoma (A2780) 
 
In order to investigate the mechanism of action underlying the cytotoxic effects of Nubein6.8, 
melanoma (A375) and ovarian carcinoma (A2780) cell lines were incubated with the peptides 
(0.01-1.8 µM, 24 hrs) for electron microscopic examination (SEM and TEM). SEM micrographs 
of A375 treated cells (Fig. 8) revealed irregularly shaped cells, rod-shaped cells, cell membrane 
blebbing, and  cellular shrinkage when compared with untreated cells. SEM of A2780 tumor cells 
(Fig. 8) treated with (EC: 0.11, 0.45, 0.9 µM)  Nubein6.8 caused surface concavity, cellular 
shrinkage, cell membrane irregularity and loss of normal characteristics. TEM studies of A375 
tumor cells (Fig. 9) (EC: 0.11, 0.45, 0.9 µM) of Nubein6.8 revealed the loss of most cell organelles, 
abnormal blebbing cell membrane and peripheral migration of the nuclear chromatin toward the 
nuclear envelope. TEM examination of A2780 tumor cells (Fig. 9) exposed to  (EC: 0.11, 0.45, 
0.9 µM) Nubein6.8 revealed an increased number of clear and empty leaking vacuoles, aggregated 
mitochondria, fragmented nuclei and loose stranded nucleoli.  
 4. Discussion 
Venom research is considered as a potential platform for drug discovery and design (Vonk 
et al., 2011, Harvey, 2014; Abdel-Rahman et al., 2015; Chen et al., 2018).  The novel finding in 
the present study was the identification of Nubein6.8 (a snake venom peptide isolated from the 
Egyptian Spitting Cobra Naja nubiae) and evaluation its antitumoral efficacy against A375 human 
malignant melanoma and A2780 human ovarian carcinoma. The molecular mass of Nubein6.8 
(6801.8 Da) and the first six amino acids was determined which revealed similarity to peptides 
(belong to the snake venom 3-FTxs) previously characterized from the venom of other African 
spitting cobras (Petras et al., 2011). Of these, NAJMO_CTX1/P01467 (6.8 kDa), 
NAJMO_CTX3/P01470 and NAJMO_CTX4/P01452 were characterized from the snake venom 
of Naja mossambica (Munawar et al., 2014). CTXs are dominate in Naja venom and constitute 
72.8% of the Black-Necked Spitting Cobra (Naja nigricollis) total venom proteins (Petras et al., 
2011). Besides, 3-FTxs (consisting of 60–74 amino acids) characterized in elapid venoms 
represent a superfamily of non-enzymatic polypeptides (Fry et al., 2003). 
 
The possible pharmaceutical applications of natural toxins have been reported for various 
venomous animals including snakes (Minea et al., 2012). The present investigation studied 
whether Nubein6.8 was able to decrease the viability and proliferation rate of tumor cells using 
MTT and clonogenic assays, respectively. The MTT results showed that the growth of A375 and 
A2780 tumor cells was significantly decreased in a concentration-dependent manner when treated 
with Nubein6.8. The potential effect of Nubein6.8 on melanoma and ovarian tumor cells 
proliferation and colony-forming ability was apparent from clonogenic assay. Thus, the clonogenic 
assay permits a distinction between cytotoxic (cell death) and cytostatic (decreased growth rate) 
effects of Nubein6.8. The cytotoxic pattern possessed by Nubein6.8 is similar to cytotoxicity 
induced by the spitting cobra venoms of Naja nigricollis and Naja mossambica venoms (Khalid et 
al., 2015). Uncontrolled division, cell invasion, angiogenesis, metastasis, and evade of apoptosis 
are significant capabilities of cancer cells and inhibiting these hallmarks may leading to the arrest 
of tumor growth (Liu et al., 2010; Circu and Aw, 2010).  
 
Interestingly, the cytotoxin of NAJMO_CTX1/P01467 showed inhibitory effect on cellular 
proteasome (Munawar et al., 2014). The cells are using ubiquitin-proteasome systems for 
maintaining cellular homeostasis (Wang and Maldonado, 2006). After envenomation by N. 
mossambica, it was supposed that NAJMO_CTX1/P01467 might be involved in the alteration of 
cellular processes through inhibiting necessary catalytic machinery of the cell (such as the 20S 
proteasome). Proteasome complex inhibition could be one of the pathways involved in cytotoxin-
mediated cell death (Munawar et al., 2014). Thus, Nubein6.8 which is like 
NAJMO_CTX1/P01467 could be a good template to develop promising anticancer agents via 
targeting cellular proteasome (Cron et al., 2013).  
  
To reveal the antitumoral mechanisms of Nubein6.8, the pro-apoptotic properties of this peptide 
(such as DNA damaging and cell cycle arrest) were determined. The activation of γH2AX 
translation has been detected in melanoma A375 and ovarian A2780 cells treated with Nubein6.8. 
Nubein6.8 constitutively activated γH2AX signaling by enhancing phosphorylation of the histone 
variant H2AX. The present study suggested that Nubein6.8 induced DNA double-strand break 
(DSB) cell death which could involve activation of γH2AX translation. This effect might be related 
to the binding of Nubein6.8 with H2AX signal molecules. As a sensitive biomarker of DNA 
damage, the estimation of cellular γH2AX levels is essential to measure teeny changes in genome 
stability (Podhorecka et al., 2010). Increased rate of H2AX phosphorylation due to death-related 
DNA fragmentation leads to rapid apoptosis.  
 
Surprisingly, the blotting analysis revealed that Nubein6.8 inhibited GAPDH signaling in both 
A375 and A2780 tumor cells. GAPDH (as bioenergetics signature; Ganapathy-Kanniappan and 
Geschwind, 2013) is a fundamental element of the glycolysis energy system which is actively used 
in various types of cancer. Birsoy et al. (2013) reported that targeting of cancer cells could be 
accomplished if anticancer agents employ a mechanism specific for cancer such as targeting tumor 
glycolysis. Anti-glycolytic agents may be used as an efficient strategy of attack in combination 
therapy. The addition of chemotherapeutic agents with glycolytic inhibitors (mainly targeting 
GAPDH) has been applied to overcome drug resistance in cancer diseases (Nakano et al., 2011). 
Also, glycolysis inhibition can transform cancer cells into sensitive forms to immunotherapy 
(Beneteau et al., 2012). To the best of our knowledge, the effect of Nubein6.8 on γH2AX and 
GAPDH signals is nearly for the first time interpreted for snake venom toxins. 
 
Further, Nubein6.8 induced cell cycle arrest of both melanoma and ovarian carcinoma cell lines 
mainly through reduction the number of cells distributed in the S phase leading to mitotic division 
disruption. The stage of cell cycle arrest induced by Nubein6.8 may explain its molecular mode of 
action. Malumbres and Barbacid (2009) reported that the arrestment of S-phase can be activated 
by the suppression of cyclin A and cyclin E via the activation of p21 (through p53 in the presence 
of DNA damage). Previously, few snake venom peptides/proteins have been characterized with 
potential effect on the progression of cell cycle such as Bothropstoxin-I (Bothrops jararacussu; 
Da Silva et al., 2015), BatroxLAAO (Bothrops atrox; Alves-Paiva et al., 2011) and ACTX-6 
(Agkistrodon acutus, Zhang and WU, 2008). More imortantly to mention that the cytotoxicity of 
nubein6.8 were confirmed by the results of labeled-nubein6.8 cellular uptaking and electron 
microscopic examinations (SEM and TEM). These imaging appraches supported the capability of 
nubein6.8 to enter the cell and disrupting the integrity of cell membrane and cellular organelles 
(such as membrane blebbing, cellular shrinkage, mitochondrial) leading to the cell death of the 
tumor cells. Taken together, the novel obtained efficacy of Nubein6.8 in reducing cancer cell 
proliferation, arresting cell cycle, inducing cancer cell DNA double breaks and apoptosis, besides 
glycolysis inhibition, may making it as a good template to develop effective anticancer agents 
targeting human melanoma and ovarian carcinoma.   
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Figure Captions  
Fig.1. Separation of the snake venom Naja nubiae and partial identification of the antitumor 
peptide Nubein6.8. (A) The crude venom of N. nubiae (50 mg dissolved in 500 µl dH2O) was 
applied on Sephadex G-50 column (1.5 x 100 cm) and equilibrated with 0.1 M Ammonium Acetate 
buffer. Venom sample was eluted at 30 ml/hr flow rate and 5 ml fractions were collected. Protein 
concentration was monitored at 280 nm. (*) Five fractions were obtained (F1-F5) and F3 
(Nubein6.8) revealed potent antitumor activity on different cell lines. (B) F3 was further purified 
by HPLC which showed a single peak of Nubein6.8 eluated at RT 58 min. (C) Molecular mass 
determination of Nubein6.8 (6801.8 Da) using MALDI/TOF-MS. (D) Nubein6.8 n-terminal amino 
acids sequencing (first 6 residues; LKCNQL) determined by Automated Edman Degradation. (E) 
Sequence alignment of the first 6 N-terminal residues of Nubein6.8 with cytotoxins purified from 
the venom of other spitting cobras. The aligned cytotoxins are UniProt:P01469 (Cytotoxin 2, 
Mozambique spitting cobra Naja mossambica; MW 6800 Da), UniProt:P01467 (Cytotoxin 1, 
Mozambique spitting cobra Naja mossambica; MW 6826 Da) and UniProt:P01468 (Cytotoxin 1, 
Red spitting cobra Naja pallida; MW 6827 Da). The BLAST analysis shows that the first 6 
residues (LKCNQL) are conserved in the aligned toxins.   
 
Fig. 2. Cytotoxicity and EC50 determination of Nubein6.8 derived from the snake venom Naja 
nubiae on cancer and normal cell lines. Effect of different concentrations (0.007-14.7 µM) of 
Nubein6.8 on cell viability of melanoma (A375), human ovarian carcinoma (A2780) and normal 
cells (PNT2) after 24 hrs incubation (37°C, 5% CO2) determined by MTT assay. Dose-response 
curves revealed that Nubein6.8 showed high selectivity to melanoma A375 (EC50 0.54 ± 0.04 µM) 
than ovarian A2780 (1.249 ± 0.06 µM) and PNT2 normal cell lines (1.45 ± 0.05 µM). Values 
represent the mean ± SEM from three independent experiments (n=3 replicates/experiment).  
 
 
Fig. 3. Morphological alterations of human melanoma (A375) and ovarian carcinoma 
(A2780) cell lines induced by Nubein6.8. A375 and A2780 tumor cells prepared at optimized 
seeding density 1x104 cells/ well in 96 well plates then incubated (37°C and 5% CO2) for 24 hrs. 
Effective concentrations (EC; 0.54 ± 0.04 and 1.249 ± 0.06 µM for A375 and A2780, respectively) 
of Nubein6.8 were added and after 24 hrs incubation, the viability of the cells was assessed and 
images taken from three independent experiments (n=3 replicates/experiment).  
 
Fig. 4. Antimetastatic potency of Nubein6.8 on human malignant melanoma (A375) and 
ovarian carcinoma (A2780) using clonogenic assay. Clonogenic assay was carried out (n= 3) 
for Nubein6.8 on A375 tumor cells and A2780 tumor cells in 60 mm petri dishes at optimized 
density 400 cells/dish. After 9 days incubation (37°C and 5% CO2), colonies formation was 
assessed and manually counted, starting with colonies developed in the negative control dishes 
and images taken. Melanoma (A375): There was an obvious effect for Nubein6.8 on A375 tumor 
cell survival appeared from the highest concentration (1.8 µM) that have no colonized cells at all, 
and the formed-colonies average numbers kept too less than the control dishes till the lowest 
concentration (0.01 µM). Comparison between the long-term effect of Nubein6.8 with control on 
A375 tumor cell survival revealed a high significant difference. Ovarian carcinoma (A2780): 
There was a moderate effect of Nubein6.8 on A2780 tumor cell survival which significantly 
appeared only at the concentrations of 0.9 µM and 1.8 µM, then the formed-colonies average 
numbers were quite near to control dishes at the rest of concentrations. Values represent the mean 
± SEM. ** Statistical analysis was performed using one-way ANOVA followed by Dunnett’s 
Multiple Comparison test (p<0.01). 
Fig. 5. DNA damage efficacy of Nubein6.8 on human malignant melanoma (A375) and 
ovarian carcinoma (A2780) using Western Blotting with Anti-phospho-Histone H2AX 
antibody. Whole pre-treated cell DNA extracts were prepared, standardized with Amidoblack 
protein assay, separated by SDS-PAGE, and assessed for phosho-Histone H2AX. (A and B) 
Western Blotting of Nubein6.8 (0.01-1.8 µM) on the phosho-Histone H2AX expression level of 
A375 tumor cells and A2780, respectively. Values represent the mean ± SEM. **Statistical 
analysis was performed using one-way ANOVA followed by Dunnett’s Multiple Comparison test 
(p<0.01). GAPDH (Glyceraldehyde-3-phosphate dehydrogenase): Western blotting loading 
control. Staurosporine: Positive DNA damaging control. 
 
Fig. 6. Genotoxicity of Nubein6.8 on human malignant melanoma (A375) and ovarian 
carcinoma (A2780) using FACS-Flow Cytometry. Cell cycle representative histogram analysis 
of A375 and A2780 tumor cells pre-treated with various concentrations (0.01-1.8 µM) of 
Nubein6.8 (n= 3). Melanoma A375: In a concentration-dependent manner, the number of cells 
distributed in the S phase remarkably decreased (2-fold decrease in melanoma) compared with 
cells in other phases. Ovarian cells: Nubein6.8 induced cell cycle blockage at S phase and 
continued to reach G2-M phase. LC: low concentrations (0.01 and 0.0.3 µM), EC: effective 
concentrations (0.11- 0.9 µM).  
 
Fig. 7. Cellular uptake of labeled-Nubein6.8 by human malignant melanoma (A375) and 
ovarian carcinoma (A2780). Cells cultured on coverslips then incubated at 37°C and 5% CO2 for 
24 hrs and then labeled-Nubein6.8 was added (from 0.01 to 1.8 µM). After 24 hrs incubation, the 
cells were fixed, stained and mounted, then images taken. There was an obvious cellular uptake of 
labeled-Nubein6.8 (green) by both A375 and A2780 tumor cells appeared in the range of effective 
concentrations (EC 0.11 - 0.9 µM). Red indicates actin cellular skeleton, and blue indicates nuclei.     
 
Fig. 8. Scanning Electron Microscopy (SEM) analysis of Nubein6.8 antitumoral efficacy on 
human malignant melanoma (A375) and ovarian carcinoma (A2780).  
SEM of control A375 tumor cells showing intact cell membrane with normal extended microvilli. 
SEM of A375 tumor cells treated by the effective concentrations (EC: 0.11, 0.45, 0.9 µM) of 
Nubein6.8 revealing irregularly shaped cells, rod-shaped cells (R), cell membrane blebbing (B) 
and irregularity and discontinuity (Dc). SEM of control A2780 tumor cells showing intact cell 
membrane with high density of different shaped (plexus-shaped (P)) complex receptors and 
structural proteins.  SEM of A2780 tumor cells treated by the effective concentrations (EC: 0.11, 
0.45, 0.9 µM) of Nubein6.8 revealing surface concavity, cellular shrinkage, cell membrane 
irregularity and loss of normal characteristics.  
 
Fig. 9. Transmission Electron Microscopy (TEM) analysis of Nubein6.8 antitumoral efficacy 
on human malignant melanoma (A375) and and ovarian carcinoma (A2780). TEM of control 
A375 tumor cells representing intact cell membrane with protruded microvilli, smoothly outlined 
nuclei (N) with normal distributed nuclear chromatin and nucleoli, abundant mitochondria (M) 
and well-preserved cytoplasmic organelles.   TEM of A375 tumor cells treated by the effective 
concentrations (EC: 0.11, 0.45, 0.9 µM) of Nubein6.8 showing the complete blockade (arrow 
heads) of external compound (which should be Nubein6.8) to the whole cell surface leading to 
loss of all internal cell compartments differentiation and disappearance of most cell organelles, 
and in other cells showing obvious abnormal blebbing cell membrane, peripheral migration of the 
nuclear chromatin toward the nuclear envelope (NE). TEM of control A2780 tumor cells 
representing intact cell membrane with some coiled and rayed gates, nuclei (N) of normally 
distributed chromatin and nucleoli, and some mitochondria (M) and lipid vacuoles were seen in 
the cytoplasm.  TEM of A2780 tumor cells treated by the effective concentrations (EC: 0.11, 0.45, 
0.9 µM) of Nubein6.8 showing cells with increased number of clear and empty leaking vacuoles 
(EV),  fragmented nuclei (F), loose stranded nucleoli (Nu). Other cells showed nuclear division 
features as nuclei can be seen of two poled parts and nucleoli (Nu) of stranded duplicated nuclear 
DNA, although of less dense chromatin, besides the aggregated number of mitochondria (M).  
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Supplementary Fig. 1. LC-MS of Naja nubiae fraction F3 (NNF3) separated by 46 
Sephadex G-50 column.  The obtained data clearly showed that the fraction F3 47 
contains only one peptide with 6.8 KD (Nubein6.8). 48 
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Supplementary Fig. 2. Morphological alterations of PANC1 pancreatic cancer cell 59 
line induced by Nubein6.8. PANC1 tumor cells prepared at optimized seeding density 60 
20000 cells/well in 96 well plates then incubated (37°C and 5% CO2) for 24 hrs. 61 
Different concentrations (0.007-14.7 µM) of Nubein6.8 were added and after 24 hrs 62 
incubation, the viability of the cells was assessed, and images taken. There was a slight 63 
cytotoxic effect of Nubein6.8 on PANC1 tumor cell viability in the high concentrations. 64 
HC; high concentrations (above 3.7 µM). EC; effective concentrations (0.11-0.9 µM), 65 
LC; low concentrations (0.007-0.06 µM). 66 
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Supplementary Fig. 3. Cytotoxicity of Nubein6.8 derived from the snake venom 85 
Naja nubiae on PANC1 pancreatic cancer cell line. Dose-response curves and 86 
determination of the median effective concentration (EC50) of Nubein6.8 on PANC1 87 
cell line from three independent experiments performed in triplicates. There was no fit 88 
EC50 and the dose response curves not determined. 89 
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Supplementary Fig. 4. Hemolytic effect of Nubein6.8 on washed sheep RBCs. No 133 
haemolytic activity was detected of Nubein6.8 on RBCs at the highest concentration 134 
tested (14.7 µM). 135 
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Supplementary Fig. 5. Anti-metastatic potency of Nubein6.8 on human malignant 150 
melanoma (A375) using clonogenic assay. Clonogenic assay was carried out (n= 3) 151 
for Nubein6.8 on A375 tumor cells in 60 mm petri dishes at optimized density 400 152 
cells/dish. After 9 days incubation (37°C and 5% CO2), colonies formation was 153 
assessed and manually counted, starting with colonies developed in the negative control 154 
dishes and images taken. There was an obvious effect for Nubein6.8 on A375 tumor 155 
cell survival appeared from the highest concentration (1.8 µM) that have no colonized 156 
cells at all, and the formed-colonies average numbers kept too less than the control 157 
dishes till the lowest concentration (0.01 µM).  158 
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Supplementary Fig. 6. Anti-metastatic potency of Nubein6.8 on human ovarian 169 
carcinoma (A2780) using clonogenic assay. Clonogenic assay was carried out (n= 3) 170 
for Nubein6.8 on A2780 tumor cells in 60 mm petri dishes at optimized density 400 171 
cells/dish. After 9 days incubation (37°C and 5% CO2), colonies formation was 172 
assessed and manually counted, starting with colonies developed in the negative control 173 
dishes and images taken. There was a moderate effect of Nubein6.8 on A2780 tumor 174 
cell survival which significantly (p<0.01) appeared only at the concentrations of 0.9 175 
µM and 1.8 µM, then the formed-colonies average numbers were quite near to control 176 
dishes at the rest of concentrations. 177 
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